188 related articles for article (PubMed ID: 21789751)
1. [Synthetic lethality as a new concept for the treatment of cancer].
Herter-Sprie GS; Chen S; Höpker K; Reinhardt HC
Dtsch Med Wochenschr; 2011 Jul; 136(30):1526-30. PubMed ID: 21789751
[TBL] [Abstract][Full Text] [Related]
2. Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer.
Hu Y; Guo M
Cancer Sci; 2020 Sep; 111(9):3111-3121. PubMed ID: 32639661
[TBL] [Abstract][Full Text] [Related]
3. Targeting the DNA damage response in oncology: past, present and future perspectives.
Basu B; Yap TA; Molife LR; de Bono JS
Curr Opin Oncol; 2012 May; 24(3):316-24. PubMed ID: 22476188
[TBL] [Abstract][Full Text] [Related]
4. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
Murai J
Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
[TBL] [Abstract][Full Text] [Related]
5. PARPi focus the spotlight on replication fork protection in cancer.
Schlacher K
Nat Cell Biol; 2017 Oct; 19(11):1309-1310. PubMed ID: 29087384
[TBL] [Abstract][Full Text] [Related]
6. An Achilles' heel for breast cancer?
Caldecott KW; Chalmers A
Nat Struct Mol Biol; 2005 May; 12(5):387-8. PubMed ID: 15870726
[No Abstract] [Full Text] [Related]
7. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
8. PARP inhibitors: targeting the right patients.
Azvolinsky A
J Natl Cancer Inst; 2012 Dec; 104(24):1851-2. PubMed ID: 23231976
[No Abstract] [Full Text] [Related]
9. c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance.
Pyndiah S; Tanida S; Ahmed KM; Cassimere EK; Choe C; Sakamuro D
Sci Signal; 2011 Mar; 4(166):ra19. PubMed ID: 21447800
[TBL] [Abstract][Full Text] [Related]
10. Synthetic lethality to overcome cancer drug resistance.
Porcelli L; Quatrale AE; Mantuano P; Silvestris N; Brunetti AE; Calvert H; Paradiso A; Azzariti A
Curr Med Chem; 2012; 19(23):3858-73. PubMed ID: 22788762
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
Bouwman P; Jonkers J
Clin Cancer Res; 2014 Feb; 20(3):540-7. PubMed ID: 24270682
[TBL] [Abstract][Full Text] [Related]
12. DNA damage repair in breast cancer and its therapeutic implications.
Ali R; Rakha EA; Madhusudan S; Bryant HE
Pathology; 2017 Feb; 49(2):156-165. PubMed ID: 28034453
[TBL] [Abstract][Full Text] [Related]
13. Genistein induces G2/M cell cycle arrest and apoptosis of human ovarian cancer cells via activation of DNA damage checkpoint pathways.
Ouyang G; Yao L; Ruan K; Song G; Mao Y; Bao S
Cell Biol Int; 2009 Dec; 33(12):1237-44. PubMed ID: 19732843
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
Drew Y; Mulligan EA; Vong WT; Thomas HD; Kahn S; Kyle S; Mukhopadhyay A; Los G; Hostomsky Z; Plummer ER; Edmondson RJ; Curtin NJ
J Natl Cancer Inst; 2011 Feb; 103(4):334-46. PubMed ID: 21183737
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol mediated cell death in cigarette smoke transformed breast epithelial cells is through induction of p21Waf1/Cip1 and inhibition of long patch base excision repair pathway.
Mohapatra P; Satapathy SR; Das D; Siddharth S; Choudhuri T; Kundu CN
Toxicol Appl Pharmacol; 2014 Mar; 275(3):221-31. PubMed ID: 24467951
[TBL] [Abstract][Full Text] [Related]
17. Methyl 3-hydroxyimino-11-oxoolean-12-en-28-oate (HIMOXOL), a synthetic oleanolic acid derivative, induces both apoptosis and autophagy in MDA-MB-231 breast cancer cells.
Lisiak N; Paszel-Jaworska A; Bednarczyk-Cwynar B; Zaprutko L; Kaczmarek M; Rybczyńska M
Chem Biol Interact; 2014 Feb; 208():47-57. PubMed ID: 24291674
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitors: will the new class of drugs match the hype?
Tuma RS
J Natl Cancer Inst; 2009 Sep; 101(18):1230-2. PubMed ID: 19738163
[No Abstract] [Full Text] [Related]
19. BRCA1 and BRCA2 mutation type associated with cancer risk.
Burki TK
Lancet Oncol; 2015 May; 16(5):e205. PubMed ID: 25892146
[No Abstract] [Full Text] [Related]
20. DNA REPAIR. Drugging DNA repair.
Jackson SP; Helleday T
Science; 2016 Jun; 352(6290):1178-9. PubMed ID: 27257245
[No Abstract] [Full Text] [Related]
[Next] [New Search]
